Karonudib

DRUG3 trials

Sponsors

Oxcia AB, Oxcia AB, Thomas Helledays Stiftelse Foer Medicinsk Forskning, Thomas Helleday Foundation

Conditions

CancerHematological malignanciesLeukemia

Phase 1

MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class

CompletedNCT03036228

Thomas Helleday FoundationCancer

Start: 2017-01-14End: 2024-12-17Updated: 2025-09-09

A Study in Leukemia Patients With Karonudib

RecruitingNCT04077307

Thomas Helleday FoundationLeukemia

Start: 2019-12-03End: 2026-12-30Target: 9Updated: 2025-12-19

MAATEO: A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib

RecruitingCTIS2024-513766-20-00

Oxcia AB, Oxcia AB, Thomas Helledays Stiftelse Foer Medicinsk ForskningHematological malignancies

Start: 2019-12-03Target: 31Updated: 2026-01-22

Related Papers

A Phase I/II Study Investigating Karonudib in Patients with Refractory Haematological Malignancies

Blood2024-11-053 citations

Abstract CT182: OXC-101 shows favorable safety profile in first in human phase 1 trial in patients with advanced solid cancer

Cancer Research2023-04-144 citations